Literature DB >> 3082226

Willingness to pay and accept risks to cure chronic disease.

M S Thompson.   

Abstract

Measurements of disease burden focus most often on economic outputs--neglecting effects on quality of life. More comprehensive quantification is based on what people would pay or risk to avoid illness. Many, however, find it difficult to respond thoughtfully to hypothetical questions about what they would pay or risk. With response rates frequently under 50 per cent, the practicality of these methods has been of concern. In this study, specially trained interviewers asked 247 subjects with rheumatoid arthritis how much of their income they would pay and how large a mortal risk they would accept to achieve a hypothetical cure. Ninety-eight per cent of the subjects estimated their maximum acceptable risk (MAR) at an average 27 per cent chance of immediate death. Eighty-four per cent gave plausible responses to the willingness-to-pay (WTP) questions, with a mean WTP of 22 per cent of household income. The aspect of disease most strongly associated with WTP was impairment in activities of daily living; measured pain was most associated with MAR. The response rates achieved indicate the overall feasibility of these methods; the associations of WTP and MAR with other variables suggest systematic consideration of personal circumstances.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082226      PMCID: PMC1646507          DOI: 10.2105/ajph.76.4.392

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  23 in total

1.  The amniocentesis decision: an explicit guide for parents.

Authors:  S P Pauker; S G Pauker
Journal:  Birth Defects Orig Artic Ser       Date:  1979

2.  Overview of adult health measures fielded in Rand's health insurance study.

Authors:  R H Brook; J E Ware; A Davies-Avery; A L Stewart; C A Donald; W H Rogers; K N Williams; S A Johnston
Journal:  Med Care       Date:  1979-07       Impact factor: 2.983

3.  Willingness to pay for reduction in fatality risk: an exploratory survey.

Authors:  A Muller; T J Reutzel
Journal:  Am J Public Health       Date:  1984-08       Impact factor: 9.308

4.  The utility of different health states as perceived by the general public.

Authors:  D L Sackett; G W Torrance
Journal:  J Chronic Dis       Date:  1978

5.  The framing of decisions and the psychology of choice.

Authors:  A Tversky; D Kahneman
Journal:  Science       Date:  1981-01-30       Impact factor: 47.728

6.  Feasibility of willingness-to-pay measurement in chronic arthritis.

Authors:  M S Thompson; J L Read; M Liang
Journal:  Med Decis Making       Date:  1984       Impact factor: 2.583

7.  Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1981-10-22       Impact factor: 91.245

8.  The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis.

Authors:  N S Hartunian; C N Smart; M S Thompson
Journal:  Am J Public Health       Date:  1980-12       Impact factor: 9.308

9.  Fallacy of the five-year survival in lung cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1978-12-21       Impact factor: 91.245

10.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02
View more
  25 in total

1.  The role of cost-consequence analysis in healthcare decision-making.

Authors:  J A Mauskopf; J E Paul; D M Grant; A Stergachis
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

2.  A quality-of-life method for estimating the value of avoided morbidity.

Authors:  M T French; J A Mauskopf
Journal:  Am J Public Health       Date:  1992-11       Impact factor: 9.308

3.  The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.

Authors:  Grace Wu; Krista L Lanctôt; Nathan Herrmann; Shehnaz Moosa; Paul I Oh
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

5.  Economic evaluation of drug therapy: a review of the contingent valuation method.

Authors:  M Johannesson; P O Johansson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

6.  Economic evaluation in healthcare. A brief history and future directions.

Authors:  K Blumenschein; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

7.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

8.  Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

Authors:  B J O'Brien; S Novosel; G Torrance; D Streiner
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

9.  'Acceptable' risk of drug treatment.

Authors:  T Pullar
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

Review 10.  Postmarketing surveillance of quinolones, 1990 to 1992.

Authors:  P Davey; T McDonald
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.